TD Cowen raised the firm’s price target on Hims & Hers to $44 from $28 and keeps a Buy rating on the shares. The firm continues to believe in the company’s long-term growth potential as it continues to expand personalization specialties and scale but think there could be near-term headwinds as commercial dosage compounded GLP-1s are likely no longer offered after 1Q25.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers price target raised to $39 from $24 at Truist
- Hims & Hers Health, Inc. Reports Strong Growth Amid Challenges
- Hims & Hers Health: Buy Rating Affirmed Amidst Strong Sales Growth and Strategic Adaptation
- Hims & Hers Health (NYSE:HIMS) Craters With Weight Loss Drug Issues
- Hims & Hers falls -26.8%